Starting Wegovy at 2.4mg: reaching the maintenance dose and what happens next

How 2.4mg fits into the full Wegovy dose ladder

Wegovy is titrated gradually because semaglutide's commonest side effects (nausea, loose stools, stomach discomfort) hit hardest when doses change. The schedule moves from 0.25mg through 0.5mg, 1mg and 1.7mg before arriving at 2.4mg, with roughly a month at each level. The starting dose is purely about tolerability; each subsequent pen is edging closer to the therapeutic target.

By the time someone reaches 2.4mg, their system has had around 12–16 weeks to adjust. Most people find GI symptoms are at their most noticeable during the earlier steps, particularly the move from 0.25mg to 0.5mg, which you can read more about on our 0.5mg guide, and have settled considerably by the time 2.4mg arrives. That is not universal, though. Some people still experience discomfort at 2.4mg, and a prescriber may recommend staying longer at 1.7mg before moving up, or pausing the increase rather than pushing through.

It is also worth knowing that the path through the full dose schedule does not have to follow the calendar rigidly. If a dose increase lands in a difficult week (a holiday, illness, a stretch of work stress) your prescriber can factor that in. There is no penalty for a slightly longer window at one level, and our guide to starting Wegovy at 1mg gives a sense of how that middle step typically unfolds.

What the trial evidence says about results at 2.4mg

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks at 2.4mg weekly. Average weight loss across participants was around 15% of starting body weight. That is a population average (some people lost considerably more, some less) and it was achieved alongside a reduced-calorie diet and increased activity, not with injections alone.

Appetite suppression is usually well established by 2.4mg. Many people report that food simply feels less central: portions that once seemed normal become difficult to finish, and the pull of habitual snacking weakens. The mechanism is semaglutide acting on GLP-1 receptors in the brain and gut, slowing how quickly the stomach empties and signalling satiety earlier in a meal. The NHS semaglutide page covers how the medicine works and what to expect in plain terms.

NICE, in its guidance on semaglutide for weight management, recommends reviewing progress at six months at the maintenance dose. If weight loss is below 5% at that point, continuing treatment needs clinical justification. Reaching 2.4mg is the start of that six-month window, not the end of the story.

The 7.2mg option: what it changes and who it is for

In January 2026 the MHRA approved a higher 7.2mg maintenance dose for Wegovy, and in April 2026 a dedicated single-dose 7.2mg pen received approval. Trials at 7.2mg reported average weight loss of around 20.7% over 72 weeks, closer to the results seen with tirzepatide at its highest dose. For context, that closes a meaningful part of the gap between what Wegovy and the dual-agonist alternative typically deliver.

The 7.2mg dose is not a separate starting point. It is available to adults with a BMI of 30 or above who have already worked through the standard titration. It is not licensed for the BMI 27–29.9 group who can access standard Wegovy with a qualifying condition. Moving to 7.2mg requires a clinical review; it is not an automatic upgrade. If you are at 2.4mg and wondering whether a higher dose is appropriate for your situation, that conversation belongs with your prescriber, ideally with some evidence of how you have responded so far.

For people on a supervised private treatment plan, the availability of 7.2mg adds a meaningful option that did not exist until this year. Specific dose availability is confirmed at consultation, no pharmacy can guarantee a particular pen format before a clinical assessment.

Side effects and safety considerations at this dose level

The GI side-effect profile at 2.4mg is largely the same as at lower doses, just potentially more pronounced for some people: nausea, stomach cramps, loose stools, constipation, and occasional burping or reflux. For most, these have quietened by the time 2.4mg is reached, though a new increase can briefly stir things up again.

Two things warrant particular attention at any maintenance dose. First, pancreatitis: the MHRA highlighted acute pancreatitis as a known, infrequent but potentially serious risk associated with GLP-1 medicines. Severe stomach pain that spreads towards the back (especially if persistent) needs urgent medical attention, not waiting to see if it passes. Second, dehydration: if nausea and vomiting are significant, keeping fluids up matters more than eating. Kidney problems can follow prolonged dehydration, so persistent severe GI illness is a reason to contact your care team promptly.

Women using oral contraceptives should be aware that semaglutide's effect on gastric emptying could, in theory, affect pill absorption, particularly around dose changes. Your prescriber and your Patient Information Leaflet are the right references for specific guidance on this. Suspected side effects can be reported at the MHRA Yellow Card service.

Our clinical team reviews progress at each repeat, not as a formality, but because what is appropriate at 2.4mg six months in may differ from what was right on day one.